Cormedix (HAM:19KA) E10: €-1.16 (As of Mar. 2026)


HAM:19KA Cormedix Inc HAM:19KA
39 GF Score
Price €6.50
GF Value €55.11
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix E10?

Cormedix HAM:19KA -8.47% 39 E10 is €-1.16 as of Mar. 2026. GuruFocus rates HAM:19KA with a GF Score™ of 39/100 and a GF Value™ of €55.11 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cormedix's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.372. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.16 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 21.30% per year. During the past 5 years, the average E10 Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cormedix was 37.30% per year. The lowest was 3.10% per year. And the median was 21.30% per year.

As of today (2026-06-27), Cormedix's current stock price is €6.502. Cormedix's E10 for the quarter that ended in Mar. 2026 was €-1.16. Cormedix's Shiller PE Ratio of today is .


Cormedix  (HAM:19KA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cormedix E10 Related Terms


Cormedix E10 Historical Data

* Premium members only.

The historical data trend for Cormedix's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cormedix E10 Chart

Cormedix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.36

Cormedix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.36 -1.16

HAM:19KA vs DSGN, SGP, PRME: E10 Comparison

For the Biotechnology subindustry, Cormedix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cormedix's Shiller PE Ratio falls into.


HAM:19KA
39GF Score
Cormedix Inc HAM:19KA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cormedix E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cormedix's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.372/330.2130*330.2130
=0.372

Current CPI (Mar. 2026) = 330.2130.

Cormedix Quarterly Data

per share eps CPI Adj_EPS
201606 -0.579 241.018 -0.793
201609 -1.025 241.428 -1.402
201612 -0.758 241.432 -1.037
201703 -0.888 243.801 -1.203
201706 -0.445 244.955 -0.600
201709 -0.713 246.819 -0.954
201712 -0.634 246.524 -0.849
201803 -0.551 249.554 -0.729
201806 -0.445 251.989 -0.583
201809 -0.463 252.439 -0.606
201812 0.088 251.233 0.116
201903 -0.195 254.202 -0.253
201906 -0.027 256.143 -0.035
201909 -1.226 256.759 -1.577
201912 -0.189 256.974 -0.243
202003 -0.190 258.115 -0.243
202006 -0.124 257.797 -0.159
202009 -0.187 260.280 -0.237
202012 -0.156 260.474 -0.198
202103 -0.168 264.877 -0.209
202106 -0.100 271.696 -0.122
202109 -0.187 274.310 -0.225
202112 -0.177 278.802 -0.210
202203 -0.163 287.504 -0.187
202206 -0.180 296.311 -0.201
202209 -0.172 296.808 -0.191
202212 -0.189 296.797 -0.210
202303 -0.224 301.836 -0.245
202306 -0.231 305.109 -0.250
202309 -0.159 307.789 -0.171
202312 -0.238 306.746 -0.256
202403 -0.230 312.332 -0.243
202406 -0.232 314.175 -0.244
202409 -0.045 315.301 -0.047
202412 0.210 315.605 0.220
202503 0.277 319.799 0.286
202506 0.243 322.561 0.249
202509 1.074 324.800 1.092
202512 0.137 324.054 0.140
202603 0.372 330.213 0.372

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.16 mean?
Cormedix (HAM:19KA) has a E10 of €-1.16 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cormedix and its competitors.
Is Cormedix's E10 too high?
Cormedix's current E10 is €-1.16. Overall, Cormedix has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cormedix's E10 compare to DSGN and SGP?
Cormedix's E10 of €-1.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cormedix and its competitors. Cormedix's current E10 is €-1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cormedix stock overvalued right now?
Based on GuruFocus' analysis, Cormedix (HAM:19KA) is currently considered Possible Value Trap. The stock's GF Value™ is €55.11, compared to a current price of €6.50 — trading 88.2% below its estimated fair value. The current E10 is €-1.16. Cormedix's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cormedix (HAM:19KA), the current E10 is €-1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €6.50 is trading 88.2% below its estimated GF Value™ of €55.11. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • E10: €-1.16
  • GF Value™: €55.11 vs. price of €6.50 (88.2% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
39GF Score

Get the complete analysis for HAM:19KA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.50
Price
€55.11
GF Value